David Reboussin to Adult
This is a "connection" page, showing publications David Reboussin has written about Adult.
Connection Strength
0.536
-
Reboussin DM, Allen NB, Griswold ME, Guallar E, Hong Y, Lackland DT, Miller EPR, Polonsky T, Thompson-Paul AM, Vupputuri S. Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018 06; 71(6):e116-e135.
Score: 0.064
-
Reboussin DM, Allen NB, Griswold ME, Guallar E, Hong Y, Lackland DT, Miller EPR, Polonsky T, Thompson-Paul AM, Vupputuri S. Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018 05 15; 71(19):2176-2198.
Score: 0.064
-
Rivers CA, Barton JC, Gordeuk VR, Acton RT, Speechley MR, Snively BM, Leiendecker-Foster C, Press RD, Adams PC, McLaren GD, Dawkins FW, McLaren CE, Reboussin DM. Association of ferroportin Q248H polymorphism with elevated levels of serum ferritin in African Americans in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Blood Cells Mol Dis. 2007 May-Jun; 38(3):247-52.
Score: 0.031
-
Reboussin DM, Goff DC, Lipkin EW, Herrington DM, Summerson J, Steffes M, Crouse RJ, Jovanovic L, Feinglos MN, Probstfield JL, Banerji MA, Pettitt DJ, Williamson J. The combination oral and nutritional treatment of late-onset diabetes mellitus (CONTROL DM) trial results. Diabet Med. 2004 Oct; 21(10):1082-9.
Score: 0.026
-
Goldston DB, Reboussin BA, Kancler C, Daniel SS, Frazier PH, Harris AE, Kelley AE, Reboussin DM. Rates and predictors of aftercare services among formerly hospitalized adolescents: a prospective naturalistic study. J Am Acad Child Adolesc Psychiatry. 2003 Jan; 42(1):49-56.
Score: 0.023
-
Rapp SR, Feldman SR, Exum ML, Fleischer AB, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999 Sep; 41(3 Pt 1):401-7.
Score: 0.018
-
Ricci PE, Burdette JH, Elster AD, Reboussin DM. A comparison of fast spin-echo, fluid-attenuated inversion-recovery, and diffusion-weighted MR imaging in the first 10 days after cerebral infarction. AJNR Am J Neuroradiol. 1999 Sep; 20(8):1535-42.
Score: 0.018
-
Wagoner KG, Reboussin DM, King JL, Orlan E, Cornacchione Ross J, Sutfin EL. Who Is Exposed to E-Cigarette Advertising and Where? Differences between Adolescents, Young Adults and Older Adults. Int J Environ Res Public Health. 2019 07 16; 16(14).
Score: 0.018
-
Moody DM, Brown WR, Challa VR, Ghazi-Birry HS, Reboussin DM. Cerebral microvascular alterations in aging, leukoaraiosis, and Alzheimer's disease. Ann N Y Acad Sci. 1997 Sep 26; 826:103-16.
Score: 0.016
-
McCall WV, Farah A, Reboussin DM. Can we teach psychiatric residents to rate seizure regularity? Convuls Ther. 1995 Dec; 11(4):248-52.
Score: 0.014
-
Loehr SP, Pope TL, Martin DF, Link KM, Monu JU, Hunter M, Reboussin D. Three-dimensional MRI of the glenoid labrum. Skeletal Radiol. 1995 Feb; 24(2):117-21.
Score: 0.013
-
Shechter A, St-Onge MP, Kuna ST, Zammit G, RoyChoudhury A, Newman AB, Millman RP, Reboussin DM, Wadden TA, Jakicic JM, Pi-Sunyer FX, Wing RR, Foster GD. Sleep architecture following a weight loss intervention in overweight and obese patients with obstructive sleep apnea and type 2 diabetes: relationship to apnea-hypopnea index. J Clin Sleep Med. 2014 Nov 15; 10(11):1205-11.
Score: 0.013
-
Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis JM, Egan CM, Espeland MA, Evans M, Foreyt JP, Ghazarian S, Gregg EW, Harrison B, Hazuda HP, Hill JO, Horton ES, Hubbard VS, Jakicic JM, Jeffery RW, Johnson KC, Kahn SE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ, Montez MG, Murillo A, Nathan DM, Patricio J, Peters A, Pi-Sunyer X, Pownall H, Reboussin D, Regensteiner JG, Rickman AD, Ryan DH, Safford M, Wadden TA, Wagenknecht LE, West DS, Williamson DF, Yanovski SZ. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013 Jul 11; 369(2):145-54.
Score: 0.012
-
Kuna ST, Reboussin DM, Borradaile KE, Sanders MH, Millman RP, Zammit G, Newman AB, Wadden TA, Jakicic JM, Wing RR, Pi-Sunyer FX, Foster GD. Long-term effect of weight loss on obstructive sleep apnea severity in obese patients with type 2 diabetes. Sleep. 2013 May 01; 36(5):641-649A.
Score: 0.012
-
McCall WV, Reboussin D, Prudic J, Haskett RF, Isenberg K, Olfson M, Rosenquist PB, Sackeim HA. Poor health-related quality of life prior to ECT in depressed patients normalizes with sustained remission after ECT. J Affect Disord. 2013 May; 147(1-3):107-11.
Score: 0.011
-
Barton JC, Leiendecker-Foster C, Reboussin DM, Adams PC, Acton RT, Eckfeldt JH. Relationships of serum free thyroxine and erythrocyte measures in euthyroid HFE C282Y homozygotes and control subjects: the HEIRS study. Int J Lab Hematol. 2010 Jun; 32(3):282-7.
Score: 0.009
-
Kramer H, Reboussin D, Bertoni AG, Marcovina S, Lipkin E, Greenway FL, Brancati FL. Obesity and albuminuria among adults with type 2 diabetes: the Look AHEAD (Action for Health in Diabetes) Study. Diabetes Care. 2009 May; 32(5):851-3.
Score: 0.009
-
McLaren GD, McLaren CE, Adams PC, Barton JC, Reboussin DM, Gordeuk VR, Acton RT, Harris EL, Speechley MR, Sholinsky P, Dawkins FW, Snively BM, Vogt TM, Eckfeldt JH. Clinical manifestations of hemochromatosis in HFE C282Y homozygotes identified by screening. Can J Gastroenterol. 2008 Nov; 22(11):923-30.
Score: 0.009
-
Barton JC, Leiendecker-Foster C, Reboussin DM, Adams PC, Acton RT, Eckfeldt JH. Thyroid-stimulating hormone and free thyroxine levels in persons with HFE C282Y homozygosity, a common hemochromatosis genotype: the HEIRS study. Thyroid. 2008 Aug; 18(8):831-8.
Score: 0.008
-
Adams PC, Reboussin DM, Barton JC, Acton RT, Speechley M, Leiendecker-Foster C, Meenan R, Passmore L, McLaren CE, McLaren GD, Gordeuk V, Dawkins F, Eckfeldt JH. Serial serum ferritin measurements in untreated HFE C282Y homozygotes in the Hemochromatosis and Iron Overload Screening Study. Int J Lab Hematol. 2008 Aug; 30(4):300-5.
Score: 0.008
-
Barton JC, Acton RT, Leiendecker-Foster C, Lovato L, Adams PC, Eckfeldt JH, McLaren CE, Reiss JA, McLaren GD, Reboussin DM, Gordeuk VR, Speechley MR, Press RD, Dawkins FW. Characteristics of participants with self-reported hemochromatosis or iron overload at HEIRS study initial screening. Am J Hematol. 2008 Feb; 83(2):126-32.
Score: 0.008
-
Adams PC, Reboussin DM, Press RD, Barton JC, Acton RT, Moses GC, Leiendecker-Foster C, McLaren GD, Dawkins FW, Gordeuk VR, Lovato L, Eckfeldt JH. Biological variability of transferrin saturation and unsaturated iron-binding capacity. Am J Med. 2007 Nov; 120(11):999.e1-7.
Score: 0.008
-
McLaren CE, Barton JC, Gordeuk VR, Wu L, Adams PC, Reboussin DM, Speechley M, Chang H, Acton RT, Harris EL, Ruggiero AM, Castro O. Determinants and characteristics of mean corpuscular volume and hemoglobin concentration in white HFE C282Y homozygotes in the hemochromatosis and iron overload screening study. Am J Hematol. 2007 Oct; 82(10):898-905.
Score: 0.008
-
Barton JC, Acton RT, Leiendecker-Foster C, Lovato L, Adams PC, McLaren GD, Eckfeldt JH, McLaren CE, Reboussin DM, Gordeuk VR, Speechley MR, Reiss JA, Press RD, Dawkins FW. HFE C282Y homozygotes aged 25-29 years at HEIRS Study initial screening. Genet Test. 2007; 11(3):269-75.
Score: 0.008
-
McLaren CE, Li KT, McLaren GD, Gordeuk VR, Snively BM, Reboussin DM, Barton JC, Acton RT, Dawkins FW, Harris EL, Eckfeldt JH, Moses GC, Adams PC. Mixture models of serum iron measures in population screening for hemochromatosis and iron overload. Transl Res. 2006 Oct; 148(4):196-206.
Score: 0.007
-
Acton RT, Barton JC, Passmore LV, Adams PC, Speechley MR, Dawkins FW, Sholinsky P, Reboussin DM, McLaren GD, Harris EL, Bent TC, Vogt TM, Castro O. Relationships of serum ferritin, transferrin saturation, and HFE mutations and self-reported diabetes in the Hemochromatosis and Iron Overload Screening (HEIRS) study. Diabetes Care. 2006 Sep; 29(9):2084-9.
Score: 0.007
-
Adams PC, Passmore L, Chakrabarti S, Reboussin DM, Acton RT, Barton JC, McLaren GD, Eckfeldt JH, Dawkins FW, Gordeuk VR, Harris EL, Leiendecker-Foster C, Gossman E, Sholinsky P. Liver diseases in the hemochromatosis and iron overload screening study. Clin Gastroenterol Hepatol. 2006 Jul; 4(7):918-23; quiz 807.
Score: 0.007
-
Barton JC, Acton RT, Lovato L, Speechley MR, McLaren CE, Harris EL, Reboussin DM, Adams PC, Dawkins FW, Gordeuk VR, Walker AP. Initial screening transferrin saturation values, serum ferritin concentrations, and HFE genotypes in Native Americans and whites in the Hemochromatosis and Iron Overload Screening Study. Clin Genet. 2006 Jan; 69(1):48-57.
Score: 0.007
-
Adams PC, Reboussin DM, Leiendecker-Foster C, Moses GC, McLaren GD, McLaren CE, Dawkins FW, Kasvosve I, Acton RT, Barton JC, Zaccaro D, Harris EL, Press R, Chang H, Eckfeldt JH. Comparison of the unsaturated iron-binding capacity with transferrin saturation as a screening test to detect C282Y homozygotes for hemochromatosis in 101,168 participants in the hemochromatosis and iron overload screening (HEIRS) study. Clin Chem. 2005 Jun; 51(6):1048-52.
Score: 0.007
-
Barton JC, Acton RT, Dawkins FW, Adams PC, Lovato L, Leiendecker-Foster C, McLaren CE, Reboussin DM, Speechley MR, Gordeuk VR, McLaren GD, Sholinsky P, Harris EL. Initial screening transferrin saturation values, serum ferritin concentrations, and HFE genotypes in whites and blacks in the Hemochromatosis and Iron Overload Screening Study. Genet Test. 2005; 9(3):231-41.
Score: 0.007
-
Sherman AM, Shumaker SA, Sharp P, Reboussin DM, Kancler C, Walkup M, Herrington DM. No effect of HRT on health-related quality of life in postmenopausal women with heart disease. Minerva Ginecol. 2003 Dec; 55(6):511-7.
Score: 0.006
-
McLaren CE, Barton JC, Adams PC, Harris EL, Acton RT, Press N, Reboussin DM, McLaren GD, Sholinsky P, Walker AP, Gordeuk VR, Leiendecker-Foster C, Dawkins FW, Eckfeldt JH, Mellen BG, Speechley M, Thomson E. Hemochromatosis and Iron Overload Screening (HEIRS) study design for an evaluation of 100,000 primary care-based adults. Am J Med Sci. 2003 Feb; 325(2):53-62.
Score: 0.006
-
Goldston DB, Daniel SS, Reboussin BA, Reboussin DM, Frazier PH, Harris AE. Cognitive risk factors and suicide attempts among formerly hospitalized adolescents: a prospective naturalistic study. J Am Acad Child Adolesc Psychiatry. 2001 Jan; 40(1):91-9.
Score: 0.005
-
Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, Furberg CD, Kowalchuk GJ, Stuckey TD, Rogers WJ, Givens DH, Waters D. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med. 2000 Aug 24; 343(8):522-9.
Score: 0.005
-
McCall WV, Reboussin DM, Weiner RD, Sackeim HA. Titrated moderately suprathreshold vs fixed high-dose right unilateral electroconvulsive therapy: acute antidepressant and cognitive effects. Arch Gen Psychiatry. 2000 May; 57(5):438-44.
Score: 0.005
-
Goldston DB, Daniel SS, Reboussin BA, Reboussin DM, Kelley AE, Frazier PH. Psychiatric diagnoses of previous suicide attempters, first-time attempters, and repeat attempters on an adolescent inpatient psychiatry unit. J Am Acad Child Adolesc Psychiatry. 1998 Sep; 37(9):924-32.
Score: 0.004
-
Challa VR, Lovell MA, Moody DM, Brown WR, Reboussin DM, Markesbery WR. Laser microprobe mass spectrometric study of aluminum and silicon in brain emboli related to cardiac surgery. J Neuropathol Exp Neurol. 1998 Feb; 57(2):140-7.
Score: 0.004
-
Goldston DB, Kelley AE, Reboussin DM, Daniel SS, Smith JA, Schwartz RP, Lorentz W, Hill C. Suicidal ideation and behavior and noncompliance with the medical regimen among diabetic adolescents. J Am Acad Child Adolesc Psychiatry. 1997 Nov; 36(11):1528-36.
Score: 0.004
-
Fleischer AB, Clark AR, Rapp SR, Reboussin DM, Feldman SR. Commercial tanning bed treatment is an effective psoriasis treatment: results from an uncontrolled clinical trial. J Invest Dermatol. 1997 Aug; 109(2):170-4.
Score: 0.004
-
Fleischer AB, Feldman SR, Rapp SR, Reboussin DM, Exum ML, Clark AR. Alternative therapies commonly used within a population of patients with psoriasis. Cutis. 1996 Sep; 58(3):216-20.
Score: 0.004
-
Fleischer AB, Feldman SR, Rapp SR, Reboussin DM, Exum ML, Clark AR, Rajashekhar V. Disease severity measures in a population of psoriasis patients: the symptoms of psoriasis correlate with self-administered psoriasis area severity index scores. J Invest Dermatol. 1996 Jul; 107(1):26-9.
Score: 0.004
-
Feldman SR, Clark A, Reboussin DM, Fleischer AB. An assessment of potential problems of home phototherapy treatment of psoriasis. Cutis. 1996 Jul; 58(1):71-3.
Score: 0.004
-
Rocco MV, Soucie JM, Reboussin DM, McClellan WM. Risk factors for hospital utilization in chronic dialysis patients. Southeastern Kidney Council (Network 6). J Am Soc Nephrol. 1996 Jun; 7(6):889-96.
Score: 0.004
-
McCall WV, Turpin E, Reboussin D, Edinger JD, Haponik EF. Subjective estimates of sleep differ from polysomnographic measurements in obstructive sleep apnea patients. Sleep. 1995 Oct; 18(8):646-50.
Score: 0.003
-
Fleischer AB, Rapp SR, Reboussin DM, Vanarthos JC, Feldman SR. Patient measurement of psoriasis disease severity with a structured instrument. J Invest Dermatol. 1994 Jun; 102(6):967-9.
Score: 0.003